Zhong Jian-Hong, Peng Ning-Fu, You Xue-Mei, Ma Liang, Xiang Xiao, Wang Yan-Yan, Gong Wen-Feng, Wu Fei-Xiang, Xiang Bang-De, Li Le-Qun
Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, China.
Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Nanning 530021, China.
Oncotarget. 2017 Mar 14;8(11):18296-18302. doi: 10.18632/oncotarget.15433.
The current clinical reality of tumor stages and primary treatments of hepatocellular carcinoma (HCC) is poorly understood. This study reviewed the distribution of tumor stages and primary treatment modalities among a large population of patients with primary HCC. Medical records of patients treated between January 2003 and October 2013 for primary HCC at our tertiary hospital in China were retrospectively reviewed. A total of 6241 patients were analyzed. The distribution of Barcelona Clinic Liver Cancer (BCLC) stages was as follows: stage 0/A, 28.9%; stage B, 16.2%; stage C, 53.6%; stage D, 1.3%. The distribution of Hong Kong Liver Cancer (HKLC) stages was as follows: stage I, 8.4%; stage IIa, 1.5%; stage IIb, 29.0%; stage IIIa, 10.0%; stage IIIb, 33.6%; stage IVa, 3.4%; stage IVb, 2.5%; stage Va, 0.2%; stage Vb, 11.4%. The most frequent therapy was hepatic resection for patients with BCLC-0/A/B disease, and transarterial chemoembolization for patients with BCLC-C disease. Both these treatments were the most frequent for patients with HKLC I to IIIb disease, while systemic chemotherapy was the most frequent first-line therapy for patients with HKLC IVa or IVb disease. The most frequent treatment for patients with HKLC Va/Vb disease was traditional Chinese medicine. In conclusion, Prevalences of BCLC-B and -C disease, and of HKLC I to IIIb disease, were relatively high in our patient population. Hepatic resection and transarterial chemoembolization were frequent first-line therapies.
目前对肝细胞癌（HCC）肿瘤分期和初始治疗的临床实际情况了解不足。本研究回顾了大量原发性HCC患者的肿瘤分期分布及初始治疗方式。对2003年1月至2013年10月在中国我院三级医院接受原发性HCC治疗的患者病历进行回顾性分析。共分析了6241例患者。巴塞罗那临床肝癌（BCLC）分期分布如下：0/A期，28.9%；B期，16.2%；C期，53.6%；D期，1.3%。香港肝癌（HKLC）分期分布如下：I期，8.4%；IIa期，1.5%；IIb期，29.0%；IIIa期，10.0%；IIIb期，33.6%；IVa期，3.4%；IVb期，2.5%；Va期，0.2%；Vb期，11.4%。对于BCLC-0/A/B期疾病患者，最常见的治疗方法是肝切除；对于BCLC-C期疾病患者，最常见的是经动脉化疗栓塞。这两种治疗方法在HKLC I至IIIb期疾病患者中也最为常见，而全身化疗是HKLC IVa或IVb期疾病患者最常见的一线治疗方法。对于HKLC Va/Vb期疾病患者，最常见的治疗方法是中药。总之，在我们的患者群体中，BCLC-B和-C期疾病以及HKLC I至IIIb期疾病的患病率相对较高。肝切除和经动脉化疗栓塞是常见的一线治疗方法。
